Details of Disease

General Information of Disease (ID: DISFREOV)

Disease Name	Mantle cell lymphoma
Synonyms	lymphoma, mantle cell; LCM; mantle zone lymphoma; MCL; mantle cell lymphoma; classical mantle cell lymphoma
Disease Class	2A85: Mature B-cell lymphoma
Definition	Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.
Disease Hierarchy	DISD8DU7: Aggressive B-cell non-Hodgkin lymphoma DISFREOV: Mantle cell lymphoma
ICD Code	ICD-11 ICD-11: 2A85.5 ICD-10 ICD-10: C83.1
Disease Identifiers	MONDO ID MONDO_0018876 MESH ID D020522 UMLS CUI C4721414 MedGen ID 1668377 Orphanet ID 52416 SNOMED CT ID 443487006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acalabrutinib	DM7GCVW	Approved	NA	[1]
Axicabtagene ciloleucel	DMYHN59	Approved	CAR T Cell Therapy	[2]
Bortezomib	DMNO38U	Approved	Small molecular drug	[3]
Ibritumomab	DMG594T	Approved	Antibody	[4]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[5]
Tecartus	DMYQCWT	Approved	CAR T Cell Therapy	[6]
Zanubrutinib	DMJWRQP	Approved	NA	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 30 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Telcyta canfosfamide	DM94IQ3	Phase 3	NA	[8]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[9]
Cirmtuzumab	DM98RW0	Phase 2	NA	[10]
INCB50465	DMZJP2T	Phase 2	NA	[10]
ISF35	DMBZK3P	Phase 2	NA	[11]
KTE-C19 CAR-T cell therapy	DMLUZJR	Phase 2	NA	[10]
P276-00	DM9DJL2	Phase 2	Small molecular drug	[12]
Polivy	DMFCIKN	Phase 2	Antibody	[13]
Zilovertamab	DMMEJ6K	Phase 2	Monoclonal antibody	[14]
Anti-CD19 CAR-T cells	DMDRYZK	Phase 1/2	CAR T Cell Therapy	[15]
Anti-CD19-CAR PBL	DM1WB8H	Phase 1/2	CAR T Cell Therapy	[16]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[17]
Anti-CD19/22-CAR vector-transduced T cells	DMMUSHR	Phase 1/2	CAR T Cell Therapy	[18]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Phase 1/2	CAR T Cell Therapy	[19]
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes	DM2YTGQ	Phase 1/2	CAR T Cell Therapy	[20]
CD19 CAR T Cells	DMUARWH	Phase 1/2	CAR T Cell Therapy	[21]
CD19.CAR T Cells	DM79GPF	Phase 1/2	CAR T Cell Therapy	[22]
CD19.CAR-T cells	DMNZ7F2	Phase 1/2	CAR T Cell Therapy	[23]
CD20-Specific CAR T Cells	DMHPZ8G	Phase 1/2	CAR T Cell Therapy	[24]
Eptacog beta	DMTY96S	Phase 1/2	Small molecular drug	[25]
GEN3013	DMZABYH	Phase 1/2	Antibody	[26]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[27]
JCARH125	DM8P7FC	Phase 1/2	CAR T Cell Therapy	[27]
PCAR-019	DM9DR13	Phase 1/2	CAR T Cell Therapy	[28]
SNS01-T	DM66DIW	Phase 1/2	NA	[29]
AMG 562	DMQ0N5Z	Phase 1	Antibody	[30]
BCL201	DMZ51EX	Phase 1	NA	[10]
Retroviral vector-transduced autologous T cells to express CD22-specific CARs	DMZ8WAQ	Phase 1	CAR T Cell Therapy	[31]
ROR1 CAR-specific Autologous T-Lymphocytes	DM5EUIY	Phase 1	CAR T Cell Therapy	[32]
Anti-CD19/20-CAR vector-transduced T cells	DM3M9OY	Clinical trial	CAR T Cell Therapy	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 30 Drug(s)

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AZ-TAK1	DMD4LGN	Investigative	NA	[34]
Curcumin-ND	DMAY0ZZ	Investigative	NA	[35]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 53 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCND3	TT1JXNR	Limited	Biomarker	[36]
CDK4	TT0PG8F	Limited	Biomarker	[37]
HDAC10	TTYHPU6	Limited	Altered Expression	[38]
MCL1	TTL53M6	Limited	Biomarker	[39]
WEE1	TTJFOAL	Limited	Biomarker	[40]
BTLA	TTER58P	moderate	Altered Expression	[41]
CD160	TTOFEAS	moderate	Altered Expression	[42]
HOXA13	TTN26OM	moderate	Biomarker	[43]
ACLY	TT0Z6Y2	Strong	Biomarker	[44]
AICDA	TTKRTP6	Strong	Biomarker	[45]
ATR	TT8ZYBQ	Strong	Altered Expression	[40]
BMI1	TTIPNSR	Strong	Altered Expression	[46]
BTK	TTGM6VW	Strong	Biomarker	[47]
CAMKK2	TTV298Y	Strong	Altered Expression	[48]
CD22	TTM6QSK	Strong	Biomarker	[49]
CD276	TT6CQUM	Strong	Biomarker	[50]
CD37	TTFCW29	Strong	Biomarker	[51]
CD38	TTPURFN	Strong	Altered Expression	[52]
CD5	TTEGYK1	Strong	Posttranslational Modification	[53]
CD74	TTCMYP9	Strong	Biomarker	[54]
CD79B	TTBN5I7	Strong	Altered Expression	[55]
CDC20	TTBKFDV	Strong	Altered Expression	[56]
CDC42BPA	TT5Z0EF	Strong	Biomarker	[57]
CHEK1	TTTU902	Strong	Biomarker	[40]
CRBN	TTDKGTC	Strong	Biomarker	[58]
CTSC	TT4H0V2	Strong	Altered Expression	[59]
DCK	TTJOCE4	Strong	Altered Expression	[60]
EGLN2	TTMHFRY	Strong	Altered Expression	[61]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[62]
EZH1	TTNJA0C	Strong	Biomarker	[63]
FCER2	TTCH6MU	Strong	Genetic Variation	[64]
GMNN	TT390KA	Strong	Altered Expression	[65]
HAX1	TT21BYA	Strong	Biomarker	[66]
HDAC6	TT5ZKDI	Strong	Biomarker	[67]
LAIR1	TTSI7A8	Strong	Genetic Variation	[68]
LTB	TTHQ6US	Strong	Altered Expression	[69]
MALT1	TTCI81G	Strong	Biomarker	[70]
MCM6	TTQGKSD	Strong	Biomarker	[71]
NCL	TTK1V5Q	Strong	Altered Expression	[72]
PDE3B	TTN34SQ	Strong	Altered Expression	[73]
PDE7B	TTWIEY9	Strong	Altered Expression	[73]
PDPK1	TTYMGWX	Strong	Biomarker	[74]
PIM2	TT69J2Z	Strong	Biomarker	[75]
PMS1	TTX1ISF	Strong	Altered Expression	[76]
PRMT5	TTR1D7X	Strong	Altered Expression	[77]
PTPRJ	TTWMKXP	Strong	Genetic Variation	[78]
ROR1	TTDEJAU	Strong	Biomarker	[79]
SCN10A	TT90XZ8	Strong	Biomarker	[80]
TCL1A	TTUKRDV	Strong	Altered Expression	[81]
TNFSF13B	TTWMIDN	Strong	Biomarker	[82]
USP2	TTUEQ1W	Strong	Biomarker	[83]
XPO1	TTCJUR4	Strong	Biomarker	[84]
ZAP70	TTUMHT8	Strong	Altered Expression	[85]
------------------------------------------------------------------------------------


⏷ Show the Full List of 53 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA6	DTLMZUF	Strong	Altered Expression	[86]
SLC35B2	DT81RKJ	Strong	Biomarker	[87]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
MGST1	DEAPJSO	Strong	Altered Expression	[88]
MT1A	DE5ME8A	Strong	Genetic Variation	[89]
------------------------------------------------------------------------------------

This Disease Is Related to 85 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DOHH	OTDRAT3F	Limited	Genetic Variation	[90]
FCRL1	OTXOYT29	Limited	Altered Expression	[91]
MEF2B	OT880SE6	Limited	Biomarker	[92]
ACSBG1	OTM040MW	moderate	Biomarker	[42]
ARHGAP29	OT8JH4TY	moderate	Posttranslational Modification	[93]
BNIP3L	OTJKOMXE	moderate	Biomarker	[93]
CCDC50	OTSE1YM5	moderate	Biomarker	[94]
MNX1	OTXP9FH1	moderate	Biomarker	[43]
MS4A4A	OTWV82RP	moderate	Biomarker	[95]
PRELP	OT9EEBUJ	moderate	Altered Expression	[96]
RAPH1	OTMQXW7S	moderate	Biomarker	[42]
ATRIP	OT78O9LF	Strong	Posttranslational Modification	[97]
BACH2	OT17GS18	Strong	Biomarker	[98]
BCL10	OT47MCLI	Strong	Biomarker	[70]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[99]
BCR	OTCN76C1	Strong	Biomarker	[100]
BIK	OTTH1T3D	Strong	Biomarker	[101]
CARD11	OTRCTLYC	Strong	Biomarker	[70]
CCND2	OTDULQF9	Strong	Altered Expression	[102]
CCNG1	OT17IA9L	Strong	Genetic Variation	[103]
CD79A	OTOJC8DV	Strong	Biomarker	[104]
CDC6	OTX93FE7	Strong	Altered Expression	[65]
CDT1	OTVY53VG	Strong	Altered Expression	[65]
CFDP1	OTXY7J96	Strong	Biomarker	[67]
CIB1	OT4BVCRU	Strong	Altered Expression	[105]
CNTNAP1	OT5Y03EU	Strong	Biomarker	[106]
CRADD	OT02TZ4S	Strong	Genetic Variation	[107]
CTNNA2	OTJ8G92T	Strong	Biomarker	[108]
DCTN6	OTI8PIN9	Strong	Biomarker	[109]
DVL2	OTMNYNCM	Strong	Altered Expression	[110]
E2F8	OTQKZGFP	Strong	Biomarker	[111]
EIF4G2	OTEO98CR	Strong	Biomarker	[67]
FBLIM1	OTFHXMON	Strong	Altered Expression	[112]
FBXO10	OTAGWV4B	Strong	Biomarker	[113]
FBXO25	OTDFA7F4	Strong	Biomarker	[66]
FUBP1	OT77SC9N	Strong	Genetic Variation	[114]
GEMIN4	OTX7402E	Strong	Biomarker	[67]
GLIS2	OTOUUV1X	Strong	Biomarker	[115]
GNAZ	OTLTDTR8	Strong	Biomarker	[116]
GOPC	OTRBGH71	Strong	Altered Expression	[112]
HACD1	OTEC7EP7	Strong	Biomarker	[117]
HILPDA	OTEID3ZM	Strong	Biomarker	[118]
IBTK	OTB2GM4G	Strong	Biomarker	[119]
IFI27	OTI2XGIT	Strong	Biomarker	[109]
IGLL5	OT9XQFL5	Strong	Biomarker	[120]
LAT2	OTWJDKIH	Strong	Altered Expression	[121]
LEF1	OTWS5I5H	Strong	Biomarker	[122]
MAP2	OT6UYT3X	Strong	Biomarker	[123]
MCPH1	OTYT3TT5	Strong	Biomarker	[124]
MLC1	OTCNZLSP	Strong	Genetic Variation	[125]
MOB3A	OTILIOXF	Strong	Altered Expression	[124]
MSX1	OT5U41ZP	Strong	Altered Expression	[115]
NECTIN2	OTIE0W6O	Strong	Altered Expression	[126]
NSD2	OTQ6SW4R	Strong	Genetic Variation	[127]
NUP214	OTWEA19O	Strong	Genetic Variation	[114]
OMP	OT7JH0DY	Strong	Altered Expression	[128]
PCNT	OTW4Z65J	Strong	Altered Expression	[48]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[129]
PIK3IP1	OTWE5G4T	Strong	Biomarker	[130]
PLSCR1	OTGY9B5T	Strong	Altered Expression	[131]
PMAIP1	OTXEE550	Strong	Altered Expression	[132]
PMCH	OT3D9SA4	Strong	Genetic Variation	[133]
PSMD2	OT6HZHN7	Strong	Biomarker	[67]
PSMD9	OT6Y5CC3	Strong	Biomarker	[109]
RAB35	OTRH1E2T	Strong	Biomarker	[134]
RAD1	OT886MA8	Strong	Biomarker	[135]
RAD51AP1	OTXM7UTD	Strong	Altered Expression	[136]
RANGAP1	OTZGD3LJ	Strong	Altered Expression	[137]
RGS13	OTPAMQ18	Strong	Biomarker	[86]
RGS18	OTJ6ZOCN	Strong	Altered Expression	[86]
RING1	OTCWTAX0	Strong	Altered Expression	[138]
RTEL1	OTI3PJCT	Strong	Biomarker	[139]
SERPINB6	OT7G55IK	Strong	Biomarker	[117]
SETMAR	OTE2MIMZ	Strong	Biomarker	[140]
SH3YL1	OTVXOONW	Strong	Biomarker	[134]
SLC7A4	OTAVC6QS	Strong	Biomarker	[141]
SMUG1	OT2YIOCQ	Strong	Biomarker	[142]
SORBS1	OTWH8762	Strong	Biomarker	[117]
SOX12	OT93P8C9	Strong	Altered Expression	[143]
SPIB	OTO4YKYI	Strong	Altered Expression	[144]
SRY	OT516T6D	Strong	Altered Expression	[145]
TCL1B	OT4CSO39	Strong	Altered Expression	[81]
TICAM2	OTK7GIJ5	Strong	Biomarker	[109]
TMED7	OTONO8E6	Strong	Biomarker	[109]
TP53INP1	OT2363Z9	Strong	Biomarker	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 85 DOT(s)

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6777).
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912).
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8	Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32.
9	ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	ClinicalTrials.gov (NCT00942409) Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
12	A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):392-7.
13	ClinicalTrials.gov (NCT04659044) Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health.
14	ClinicalTrials.gov (NCT03088878) A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies. U.S.National Institutes of Health.
15	ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
16	ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
17	ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
18	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
19	ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
20	ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
21	ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
22	ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
23	ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
24	ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
25	ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
28	ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
29	ClinicalTrials.gov (NCT01435720) Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL). U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT03571828) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma. U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
32	ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
33	ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2082).
35	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
36	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.Virchows Arch. 2020 May;476(5):667-681. doi: 10.1007/s00428-019-02704-8. Epub 2019 Nov 26.
37	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28.
38	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies.Methods Mol Biol. 2016;1436:129-45. doi: 10.1007/978-1-4939-3667-0_10.
39	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.Oncogene. 2020 Feb;39(9):2009-2023. doi: 10.1038/s41388-019-1122-x. Epub 2019 Nov 26.
40	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.
41	High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.Am J Clin Pathol. 2009 Oct;132(4):589-96. doi: 10.1309/AJCPPHKGYYGGL39C.
42	Differential and tumor-specific expression of CD160 in B-cell malignancies.Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.
43	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.Am J Hematol. 2012 Apr;87(4):361-7. doi: 10.1002/ajh.23115. Epub 2012 Feb 28.
44	Kinematic effects of repeated turns while running.Eur J Sport Sci. 2019 Sep;19(8):1072-1081. doi: 10.1080/17461391.2019.1578416. Epub 2019 Mar 5.
45	Phosphatidylinositol 3-kinase blockade increases genomic instability in B cells.Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.
46	Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.Oncotarget. 2018 Jun 19;9(47):28547-28560. doi: 10.18632/oncotarget.25558. eCollection 2018 Jun 19.
47	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.Expert Opin Pharmacother. 2020 Jan;21(1):29-38. doi: 10.1080/14656566.2019.1689959. Epub 2019 Nov 18.
48	Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma.Int J Cancer. 2007 Apr 15;120(8):1669-77. doi: 10.1002/ijc.22404.
49	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Oncotarget. 2017 May 9;8(19):30644-30655. doi: 10.18632/oncotarget.16141.
50	MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3.Biochem Biophys Res Commun. 2019 Jan 22;508(4):1067-1073. doi: 10.1016/j.bbrc.2018.12.055. Epub 2018 Dec 12.
51	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.Blood. 2010 Aug 19;116(7):1025-34. doi: 10.1182/blood-2009-12-257485. Epub 2010 Apr 28.
52	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284. doi: 10.1016/j.clml.2018.12.013. Epub 2019 Jan 2.
53	Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.Am J Clin Pathol. 2005 May;123(5):646-50.
54	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.Exp Hematol. 2015 Sep;43(9):770-4.e2. doi: 10.1016/j.exphem.2015.04.008. Epub 2015 Apr 29.
55	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.Clin Cancer Res. 2019 Dec 1;25(23):7046-7057. doi: 10.1158/1078-0432.CCR-19-1337. Epub 2019 Aug 22.
56	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.
57	Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma.J Hematol Oncol. 2016 Mar 29;9:30. doi: 10.1186/s13045-016-0260-7.
58	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.EBioMedicine. 2017 Jun;20:70-78. doi: 10.1016/j.ebiom.2017.04.037. Epub 2017 May 10.
59	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.Int J Cancer. 2018 Jan 1;142(1):202-213. doi: 10.1002/ijc.31044. Epub 2017 Oct 16.
60	Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Mol Cancer. 2014 Jun 27;13:159. doi: 10.1186/1476-4598-13-159.
61	Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.J Cell Mol Med. 2019 Nov;23(11):7785-7795. doi: 10.1111/jcmm.14655. Epub 2019 Sep 13.
62	Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-B and mTOR dual-targeting approach.Mol Cancer Ther. 2013 Oct;12(10):2006-17. doi: 10.1158/1535-7163.MCT-13-0239. Epub 2013 Aug 20.
63	Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma.Cancer Biol Med. 2019 Aug;16(3):530-541. doi: 10.20892/j.issn.2095-3941.2018.0380.
64	SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.Am J Surg Pathol. 2019 May;43(5):710-716. doi: 10.1097/PAS.0000000000001233.
65	Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability.Int J Cancer. 2006 Dec 15;119(12):2768-74. doi: 10.1002/ijc.22146.
66	Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.Nat Med. 2014 Dec;20(12):1401-9. doi: 10.1038/nm.3740. Epub 2014 Nov 24.
67	Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.Leukemia. 2019 Jul;33(7):1675-1686. doi: 10.1038/s41375-018-0355-y. Epub 2019 Jan 21.
68	A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients.Medicine (Baltimore). 2019 May;98(22):e15811. doi: 10.1097/MD.0000000000015811.
69	Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.Haematologica. 2003 Jun;88(6):654-8.
70	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.
71	Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma.Br J Cancer. 2005 Oct 17;93(8):939-45. doi: 10.1038/sj.bjc.6602795.
72	Cyclin D1 transcriptional activation in MCL.Blood. 2014 Mar 27;123(13):1979-80. doi: 10.1182/blood-2014-02-553057.
73	High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.Leuk Res. 2013 May;37(5):536-40. doi: 10.1016/j.leukres.2013.02.006. Epub 2013 Feb 28.
74	Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.Exp Hematol. 2018 Mar;59:72-81.e2. doi: 10.1016/j.exphem.2017.12.006. Epub 2017 Dec 26.
75	Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.Blood. 2012 Oct 25;120(17):3491-500. doi: 10.1182/blood-2012-02-412643. Epub 2012 Sep 6.
76	Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin.Leuk Lymphoma. 2002 Feb;43(2):393-9. doi: 10.1080/10428190290006215.
77	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.J Biol Chem. 2020 Jan 31;295(5):1165-1180. doi: 10.1074/jbc.RA119.008742. Epub 2019 Dec 10.
78	Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.Int J Clin Exp Pathol. 2015 Jun 1;8(6):7494-8. eCollection 2015.
79	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.J Immunol. 2019 Oct 15;203(8):2043-2048. doi: 10.4049/jimmunol.1801327. Epub 2019 Sep 18.
80	Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.Cancer Res. 2010 Aug 15;70(16):6587-97. doi: 10.1158/0008-5472.CAN-09-3578. Epub 2010 Jul 27.
81	TCL1 expression predicts overall survival in patients with mantle cell lymphoma.Eur J Haematol. 2015 Dec;95(6):583-94. doi: 10.1111/ejh.12539. Epub 2015 Mar 16.
82	Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.Cancer Lett. 2012 Sep 28;322(2):159-68. doi: 10.1016/j.canlet.2012.02.029. Epub 2012 Mar 1.
83	Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.J Biol Chem. 2016 Nov 18;291(47):24628-24640. doi: 10.1074/jbc.M116.738567. Epub 2016 Sep 28.
84	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IB.Mol Cancer Ther. 2018 Dec;17(12):2564-2574. doi: 10.1158/1535-7163.MCT-17-0789-ATR.
85	Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.Clin Cancer Res. 2008 Nov 1;14(21):6907-15. doi: 10.1158/1078-0432.CCR-08-0388.
86	High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.Leukemia. 2003 Sep;17(9):1880-90. doi: 10.1038/sj.leu.2403057.
87	Ibrutinib in CLL/SLL: From bench to bedside (Review).Oncol Rep. 2019 Dec;42(6):2213-2227. doi: 10.3892/or.2019.7364. Epub 2019 Oct 10.
88	Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.Cancer Genomics Proteomics. 2018 May-Jun;15(3):213-223. doi: 10.21873/cgp.20080.
89	Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Franais d'Hmatologie Cellulaire (GFHC) study.Br J Haematol. 1998 Jun;101(4):712-21. doi: 10.1046/j.1365-2141.1998.00764.x.
90	Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003.Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2311-2321. doi: 10.1007/s00259-019-04417-1. Epub 2019 Jul 15.
91	Evaluation of CD307a expression patterns during normal B-cell maturation and in B-cell malignancies by flow cytometry.Cytometry B Clin Cytom. 2018 Jul;94(4):588-595. doi: 10.1002/cyto.b.21631. Epub 2018 Mar 9.
92	Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.Am J Surg Pathol. 2018 Mar;42(3):342-350. doi: 10.1097/PAS.0000000000001015.
93	Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. Haematologica. 2007 Apr;92(4):460-8. doi: 10.3324/haematol.10337.
94	Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.Leukemia. 2009 Nov;23(11):2018-26. doi: 10.1038/leu.2009.144. Epub 2009 Jul 30.
95	MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Immunol Cell Biol. 2017 Aug;95(7):611-619. doi: 10.1038/icb.2017.18. Epub 2017 Mar 17.
96	A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.PLoS One. 2013 Jun 24;8(6):e67601. doi: 10.1371/journal.pone.0067601. Print 2013.
97	The interaction between ATRIP and MCM complex is essential for ATRIP chromatin loading and its phosphorylation in mantle cell lymphoma cells.Pharmazie. 2017 Nov 1;72(11):670-673. doi: 10.1691/ph.2017.7676.
98	Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.Blood. 2017 Aug 10;130(6):763-776. doi: 10.1182/blood-2017-02-767293. Epub 2017 Jun 7.
99	Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.Hum Pathol. 2019 Nov;93:54-64. doi: 10.1016/j.humpath.2019.08.008. Epub 2019 Aug 16.
100	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.Mol Cancer Ther. 2019 Feb;18(2):267-277. doi: 10.1158/1535-7163.MCT-18-0478. Epub 2018 Nov 9.
101	Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.Cell Death Dis. 2014 Aug 28;5(8):e1389. doi: 10.1038/cddis.2014.346.
102	Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas.Oncol Rep. 2016 May;35(5):2673-80. doi: 10.3892/or.2016.4658. Epub 2016 Mar 7.
103	Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias.Blood. 1994 Jun 15;83(12):3689-96.
104	SOX11 augments BCR signaling to drive MCL-like tumor development.Blood. 2018 May 17;131(20):2247-2255. doi: 10.1182/blood-2018-02-832535. Epub 2018 Apr 3.
105	Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.
106	Molecular hematology. Qualitative to quantitative techniques.Saudi Med J. 2005 Oct;26(10):1516-22.
107	Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray.Blood. 2001 Aug 1;98(3):787-94. doi: 10.1182/blood.v98.3.787.
108	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):48-52. doi: 10.1016/j.clml.2018.10.006. Epub 2018 Oct 17.
109	Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.J Cell Commun Signal. 2019 Sep;13(3):421-434. doi: 10.1007/s12079-018-0494-y. Epub 2018 Nov 21.
110	Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma.Blood. 2008 Dec 15;112(13):5171-9. doi: 10.1182/blood-2008-02-139212. Epub 2008 Sep 11.
111	Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.Am J Transl Res. 2019 Jul 15;11(7):4382-4396. eCollection 2019.
112	Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.Am J Hematol. 2012 Jun;87(6):604-9. doi: 10.1002/ajh.23176.
113	FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.Oncogene. 2016 Dec 1;35(48):6223-6234. doi: 10.1038/onc.2016.155. Epub 2016 May 9.
114	Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.Int J Cancer. 2016 Nov 15;139(10):2252-60. doi: 10.1002/ijc.30263. Epub 2016 Aug 2.
115	Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma.Leuk Lymphoma. 2014 Aug;55(8):1893-903. doi: 10.3109/10428194.2013.864762. Epub 2014 Feb 17.
116	Expression of GNAZ, encoding the G(z) protein, predicts survival in mantle cell lymphoma.Br J Haematol. 2019 May;185(4):708-712. doi: 10.1111/bjh.15810. Epub 2019 Feb 20.
117	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.
118	SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.Leuk Lymphoma. 2016 Aug;57(8):1883-92. doi: 10.3109/10428194.2015.1121257. Epub 2016 Jan 12.
119	Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.PLoS One. 2019 Feb 20;14(2):e0211228. doi: 10.1371/journal.pone.0211228. eCollection 2019.
120	Mantle cell lymphoma cell lines show no evident immunoglobulin heavy chain stereotypy but frequent light chain stereotypy.Leuk Lymphoma. 2013 Aug;54(8):1747-55. doi: 10.3109/10428194.2012.758843. Epub 2013 Jan 23.
121	The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma.Leuk Lymphoma. 2019 Nov;60(11):2658-2668. doi: 10.1080/10428194.2019.1607326. Epub 2019 May 7.
122	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.Cytometry B Clin Cytom. 2018 Jan;94(1):148-150. doi: 10.1002/cyto.b.21512. Epub 2017 Feb 24.
123	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma.Br J Haematol. 2009 Feb;144(3):317-31. doi: 10.1111/j.1365-2141.2008.07443.x. Epub 2008 Nov 7.
124	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.Blood. 2010 Aug 12;116(6):953-61. doi: 10.1182/blood-2010-01-263806. Epub 2010 Apr 26.
125	Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.Diagn Mol Pathol. 2003 Mar;12(1):35-43. doi: 10.1097/00019606-200303000-00005.
126	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.
127	Genomic landscape and prognostic analysis of mantle cell lymphoma.Cancer Gene Ther. 2018 Jun;25(5-6):129-140. doi: 10.1038/s41417-018-0022-5. Epub 2018 May 14.
128	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. doi: 10.1186/s13046-019-1458-7.
129	MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFB Activation in Breast Cancer.Mol Cancer Ther. 2015 Jun;14(6):1454-65. doi: 10.1158/1535-7163.MCT-14-1053. Epub 2015 Apr 2.
130	Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. doi: 10.4161/cc.24928. Epub 2013 May 15.
131	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma.Oncotarget. 2016 Jul 5;7(27):41913-41928. doi: 10.18632/oncotarget.9630.
132	Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.
133	Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.Am J Surg Pathol. 2019 Oct;43(10):1421-1428. doi: 10.1097/PAS.0000000000001312.
134	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.Leuk Lymphoma. 2017 Dec;58(12):2824-2832. doi: 10.1080/10428194.2017.1326034. Epub 2017 May 30.
135	The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.Leukemia. 2020 May;34(5):1315-1328. doi: 10.1038/s41375-019-0677-4. Epub 2019 Dec 13.
136	Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks.Mutat Res. 2006 Oct 10;601(1-2):113-24. doi: 10.1016/j.mrfmmm.2006.06.016. Epub 2006 Aug 21.
137	Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One. 2013 Nov 6;8(11):e79863. doi: 10.1371/journal.pone.0079863. eCollection 2013.
138	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.Br J Haematol. 2001 Mar;112(4):950-8. doi: 10.1046/j.1365-2141.2001.02641.x.
139	Epidemiologic characteristics of malignant lymphoma in Hubei, China: A single-center 5-year retrospective study.Medicine (Baltimore). 2018 Aug;97(35):e12120. doi: 10.1097/MD.0000000000012120.
140	Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.PLoS One. 2010 Nov 22;5(11):e14085. doi: 10.1371/journal.pone.0014085.
141	Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation.Leuk Res. 2000 Jan;24(1):27-31. doi: 10.1016/s0145-2126(99)00156-3.
142	Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.Br J Haematol. 2020 Mar;188(6):860-871. doi: 10.1111/bjh.16257. Epub 2019 Nov 16.
143	SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression.Sci Rep. 2013;3:1400. doi: 10.1038/srep01400.
144	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-B activity.BMC Cancer. 2018 Apr 25;18(1):466. doi: 10.1186/s12885-018-4346-1.
145	Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma.Histopathology. 2019 Nov;75(5):704-714. doi: 10.1111/his.13935. Epub 2019 Aug 19.